INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS

Author:

Lee Eudocia1,Chukwueke Ugonma1,Hervey-Jumper Shawn2,DeGroot John3,Leone Pablo1,Armstrong Terri4,Chang Susan5,Arons David6,Oliver Kathy7,Verble Kay8,Musella Al9,Willmarth Nicole10,Alexander Brian1,Bates Amanda6,Doherty Lisa1,Galanis Evanthia11,Gaffey Sarah1,Halkin Thomas6,Friday Bret12,Fouladi Maryam13,Lin Nancy1,Macdonald David14,Mehta Minesh15,Penas-Prado Marta4,Vogelbaum Michael16,Sahebjam Solmaz16,Sandak David17,van den Bent Martin18,Weller Michael19,Reardon David1,Wen Patrick1

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA, USA

2. Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA

3. University of Texas MD Anderson Cancer Center, Houston, TX, USA

4. Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

5. UCSF, San Francisco, CA, USA

6. National Brain Tumor Society, Newton, MA, USA

7. IBTA, Tadworth, Wales, United Kingdom

8. The Sontag Foundation and Brain Tumor Network, Ponte Vedre Beach, FL, USA

9. The Musella Foundation for Brain Tumor Research and Information, Hewlett, NY, USA

10. American Brain Tumor Association, Chicago, IL, USA

11. Mayo Clinic, Rochester, MN, USA

12. Essentia Health, Duluth, MN, USA

13. Cincinnati Children’s Hospital, Cincinnati, USA

14. London Regional Cancer Program, London, Ontario, Canada

15. Miami Cancer Institute, Miami, FL, USA

16. Moffitt Cancer Center, Tampa, FL, USA

17. Accelerate Brain Cancer Cure (ABC2), Washington, DC, USA

18. Erasmus University Medical Center, Rotterdam, Netherlands

19. Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland

Abstract

Abstract BACKGROUND A major impediment to improving neuro-oncology outcomes is poor clinical trial accrual. METHODS We convened a multi-stakeholder group including Society for Neuro-Oncology, Response Assessment in Neuro-Oncology, patient advocacy groups, clinical trial cooperative groups, and other partners to determine how we can improve trial accrual. RESULTS We described selected factors contributing to poor trial accrual and possible solutions. We focused on patient and community factors, disparities, physician and provider factors, clinical trial factors, and site and organizational factors CONCLUSIONS We will implement strategies with the intent to double accrual to neuro-oncology trials over the next 5 years.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3